Save
Email
Print
ShareDec. 11, 2006 — In the wake of the Australian Senate’s decision to pass the human embryo cloning legislation, another Australian research breakthrough is likely to strengthen the case for embryonic stem cell research.
University of New South Wales (UNSW) academics have proven that tumours can be prevented from forming when embryonic stem cells are transplanted.
“Whilst embryonic stem cells have great potential to deliver therapies for disorders, such as diabetes, a fear has been that they will form tumours because of the presence of undifferentiated cells,” said UNSW Professor Bernie Tuch of the Diabetes Transplant Unit, who led the team responsible for the discovery.
“The passing of the legislation in the Senate last night is extremely encouraging,” said Professor Tuch. “Our breakthrough removes what could have been a stumbling block to this vital research.”
The team has shown that placing the embryonic cells inside microcapsules made from a product of seaweed, called alginate, prevents the formation of tumours when the encapsulated cells are transplanted into laboratory animals. The team has also shown that the encapsulation process does not stop the embryonic cells from differentiating.
The data describing the experiments has been published in the North American journal Transplantation, the official journal of the international Transplantation Society.
The team used both human and mouse embryonic stem cells to perform their experiments. The human embryonic stem cells were supplied by a member of the team, Chief Hospital Scientist, Dr Kuldip Sidhu, who earlier this year reported producing clones from these stem cells.
The other authors on the paper were Sophia Dean, Yulyana Yulyana and Georgia Williams.
About microencapsulation
The platform technology of microencapsulation is the same as that which the Diabetes Transplant Unit is using to transplant insulin-producing cells isolated from donor humans into insulin-dependent diabetic people, without using anti-rejection drugs. This Seaweed Diabetes Pilot Trial, which involves 6 people with diabetes, commenced in February this year and is expected to be completed within the next 18 months.
Other social bookmarking and sharing tools:
Story Source:
The above story is reprinted from materials provided by University of New South Wales.
Note: Materials may be edited for content and length. For further information, please contact the source cited above.
Note: If no author is given, the source is cited instead.
more 
